| Revenue growth | 13.9% YoY |
|---|---|
| Margins | EBITDA margins improved 240 bps YoY to 15.0% |
| Demand visibility | Healthy demand environment in CDMO segment |
| Management confidence | High; confident in structural attractiveness of chosen geographies |
Growth
Revenue grew 13.9% YoY to Rs 1,167 Cr; EBITDA rose 35.4% YoY to Rs 175 Cr with margins improving to 15.0%.
Outlook
Acquisition of Oriflame India manufacturing for Rs 56 Cr; expect improved performance in branded formulations; CDMO capacity utilization improved to 50%.
Risks
API price volatility remains high in Q2; International and domestic branded segments showed muted performance this quarter.
Last quarter's promises, checked
Delivered
- Guided H1 FY27 double-digit volume growth → delivered 13.9% revenue growth (= BEAT)
- Guided API price bounce back in Q1 → delivered improved API prices noted in Q1 (= BEAT)
- Guided CDMO margin profile sustainability → delivered EBITDA margin improvement to 15% (= BEAT)
Partly delivered
- Guided API segment turnaround → delivered nearing EBITDA positivity but not yet achieved (= PARTIAL)
Missed
- Guided domestic branded growth above IPM → delivered 7.3% growth vs 13.9% group avg (= MISS)
Investor Presentation filed with BSE, NSE: AKUMS. Summary written with AI assistance from the document.
Akums Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹821.50
- Market cap
- ₹12,930 Cr
- Revenue (annual)
- ₹4,359 Cr
- Net profit (annual)
- ₹255.2 Cr
- P/E (TTM)
- 44.3×Sector 47.4×
- Promoter holding
- 75.26%+0.00% QoQ
- FII holding
- 1.91%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Akums Drugs & Pharmaceuticals Ltd
All →Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals received an ESG rating of 65 for FY2025-26 from NSE Sustainability Ratings & Analytics Limited. The rating was assigned voluntarily based on publicly available information.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Limited has cancelled its participation in the Antique Healthcare Investor Conference scheduled for August 25, 2026, due to unavoidable medical reasons.
Akums Drugs & Pharmaceuticals Earnings Call Transcript: Key Takeaways
Akums reported strong Q1FY27 performance with 13.9% revenue growth and 56.1% PAT increase. Results were driven by a robust 18.6% growth in the CDMO segment and improved API pricing.
Akums Drugs & Pharmaceuticals Other Announcement
The company filed its quarterly shareholding pattern for the period ended September 30, 2025, in compliance with SEBI LODR regulations.
Akums Drugs & Pharmaceuticals Results Update
Akums Drugs reported Q1 FY27 consolidated revenue of ₹1,167 crore, reflecting 13.9% year-on-year growth. PAT rose to ₹101 crore compared to ₹65 crore in Q1 FY26.
Akums Drugs & Pharmaceuticals Q1 FY27 Results: Net Profit ₹101 Cr, Up 56.1% YoY
Akums Drugs & Pharmaceuticals Ltd reported revenue from operations of ₹1,167 Cr (+13.9% YoY) and net profit of ₹101 Cr (+56.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹101 Cr · +56.1% YoY